Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;55(2):305-310.
doi: 10.1161/STROKEAHA.123.045513. Epub 2024 Jan 22.

Focused Update on Intracranial Atherosclerosis: Introduction, Highlights, and Knowledge Gaps

Brian L Hoh  1 , Marc I Chimowitz  2
Affiliations
Review

Focused Update on Intracranial Atherosclerosis: Introduction, Highlights, and Knowledge Gaps

Brian L Hoh et al. Stroke. 2024 Feb.
No abstract available

Keywords: antithrombotic agents; cerebral revascularization; intracranial atherosclerosis; prevalence; randomized clinical trials; risk factors; stroke.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Hoh is receiving salary and research support as a multiple principal investigator for the ongoing National Institutes of Health (NIH)–funded CAPTIVA trial (Comparison of Anticoagulation and Antiplatelet Therapies for Intracranial Vascular Atherostenosis). AstraZeneca is supplying ticagrelor and Janssen Pharmaceutical is supplying rivaroxaban for the CAPTIVA trial. Dr Chimowitz received salary support as Principal Investigator of the NIH funded WASID (Warfarin Aspirin Symptomatic Intracranial Disease), NIH Wingspan Registry, and SAMMPRIS (Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis) studies. Bayer supplied aspirin and Bristol Myers Squibb supplied warfarin for the WASID trial; AstraZeneca supplied rosuvastatin and Stryker Corporation supplied the Wingspan stenting system for the SAMMPRIS trial. Dr Chimowitz is also receiving salary support as a multiple principal investigator for the ongoing NIH funded CAPTIVA trial. AstraZeneca is supplying ticagrelor, and Janssen Pharmaceutical is supplying rivaroxaban for the CAPTIVA trial.

References

    1. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: A large worldwide burden but a relatively neglected frontier. Stroke. 2008;39:2396–2399 - PubMed
    1. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. New England Journal of Medicine. 2011;365:993–1003 - PMC - PubMed
    1. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial. Lancet (London, England). 2014;383:333–341 - PMC - PubMed
    1. Suri MF, Johnston SC. Epidemiology of intracranial stenosis. J Neuroimaging. 2009;19 Suppl 1:11s–16s - PubMed
    1. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol. 2007;61:403–410 - PubMed

MeSH terms